Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 in chronic rhinosinusitis with nasal polyps
NCT06451640Phase 2Completed
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of bosakitug in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoint: Treatment-related adverse event rate at 36 weeks. Started Jul 2024; status: completed.
02
Drugs
bosakitug
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06451640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451640.